Tianjin Chase Sun Pharmaceutical Co.,Ltd (300026.SZ)
CNY 3.29
(4.44%)
CNY 3.29
(4.44%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 1.04 Billion CNY | -26.89% |
| 2022 | 1.13 Billion CNY | -12.85% |
| 2021 | 1.2 Billion CNY | 32.32% |
| 2020 | 903.47 Million CNY | 21.9% |
| 2019 | 653.36 Million CNY | 3.09% |
| 2018 | 466.57 Million CNY | -2.64% |
| 2017 | 705.82 Million CNY | -9.35% |
| 2016 | 900.83 Million CNY | 26.56% |
| 2015 | 685.04 Million CNY | 21.7% |
| 2014 | 570.96 Million CNY | 27.24% |
| 2013 | 453.8 Million CNY | 35.28% |
| 2012 | 333.02 Million CNY | 72.34% |
| 2011 | 196.99 Million CNY | 33.87% |
| 2010 | 146.01 Million CNY | 52.94% |
| 2009 | 96.57 Million CNY | 13.9% |
| 2008 | 86.46 Million CNY | 59.68% |
| 2007 | 53.75 Million CNY | 188.32% |
| 2006 | 15.77 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | 43.56 Million CNY | -78.31% |
| 2024 Q2 | 181.07 Million CNY | 26.04% |
| 2024 Q1 | 119.44 Million CNY | 32.78% |
| 2023 Q3 | 224.74 Million CNY | -1.65% |
| 2023 FY | - CNY | -26.89% |
| 2023 Q1 | 222.05 Million CNY | -0.87% |
| 2023 Q2 | 228.5 Million CNY | 2.91% |
| 2023 Q4 | 18.18 Million CNY | -91.91% |
| 2022 Q2 | 152 Million CNY | -49.88% |
| 2022 Q1 | 303.29 Million CNY | 22.99% |
| 2022 Q3 | 192.44 Million CNY | 26.61% |
| 2022 FY | - CNY | -12.85% |
| 2022 Q4 | 224.01 Million CNY | 16.41% |
| 2021 Q4 | 246.59 Million CNY | -7.77% |
| 2021 Q3 | 267.35 Million CNY | -19.5% |
| 2021 Q1 | 244.77 Million CNY | 346.15% |
| 2021 Q2 | 332.11 Million CNY | 35.68% |
| 2021 FY | - CNY | 32.32% |
| 2020 Q1 | 149.67 Million CNY | 282.55% |
| 2020 Q3 | 331.25 Million CNY | 11.59% |
| 2020 Q4 | 54.86 Million CNY | -83.44% |
| 2020 FY | - CNY | 21.9% |
| 2020 Q2 | 296.84 Million CNY | 98.32% |
| 2019 Q1 | 211.22 Million CNY | 152.15% |
| 2019 Q4 | 39.12 Million CNY | -81.92% |
| 2019 Q3 | 216.45 Million CNY | -0.69% |
| 2019 Q2 | 217.95 Million CNY | 3.19% |
| 2019 FY | - CNY | 3.09% |
| 2018 Q2 | 220.96 Million CNY | 1.93% |
| 2018 FY | - CNY | -2.64% |
| 2018 Q4 | 83.76 Million CNY | -48.7% |
| 2018 Q3 | 163.3 Million CNY | -26.1% |
| 2018 Q1 | 216.77 Million CNY | 29.33% |
| 2017 FY | - CNY | -9.35% |
| 2017 Q1 | 165.12 Million CNY | -41.02% |
| 2017 Q2 | 174.12 Million CNY | 5.45% |
| 2017 Q4 | 167.61 Million CNY | -24.65% |
| 2017 Q3 | 222.44 Million CNY | 27.75% |
| 2016 Q3 | 203.12 Million CNY | -9.29% |
| 2016 FY | - CNY | 26.56% |
| 2016 Q4 | 279.96 Million CNY | 37.83% |
| 2016 Q2 | 223.94 Million CNY | 37.96% |
| 2016 Q1 | 162.32 Million CNY | 3.86% |
| 2015 Q3 | 202.59 Million CNY | 0.71% |
| 2015 FY | - CNY | 21.7% |
| 2015 Q2 | 201.16 Million CNY | 78.26% |
| 2015 Q1 | 112.85 Million CNY | -25.16% |
| 2015 Q4 | 156.28 Million CNY | -22.86% |
| 2014 Q4 | 150.79 Million CNY | 9.53% |
| 2014 Q2 | 175.52 Million CNY | 83.25% |
| 2014 Q1 | 95.78 Million CNY | -12.83% |
| 2014 FY | - CNY | 27.24% |
| 2014 Q3 | 137.67 Million CNY | -21.56% |
| 2013 FY | - CNY | 35.28% |
| 2013 Q4 | 109.87 Million CNY | 8.26% |
| 2013 Q1 | 78.95 Million CNY | 23.55% |
| 2013 Q2 | 132.09 Million CNY | 67.3% |
| 2013 Q3 | 101.49 Million CNY | -23.17% |
| 2012 Q4 | 63.91 Million CNY | -33.41% |
| 2012 Q2 | 104.68 Million CNY | 69.98% |
| 2012 Q1 | 61.58 Million CNY | 9.4% |
| 2012 FY | - CNY | 72.34% |
| 2012 Q3 | 95.97 Million CNY | -8.32% |
| 2011 Q2 | 37.53 Million CNY | 14.06% |
| 2011 Q4 | 56.29 Million CNY | -4.19% |
| 2011 FY | - CNY | 33.87% |
| 2011 Q1 | 32.91 Million CNY | -44.93% |
| 2011 Q3 | 58.76 Million CNY | 56.54% |
| 2010 Q2 | 22.61 Million CNY | 61.64% |
| 2010 Q4 | 59.76 Million CNY | 38.35% |
| 2010 Q3 | 43.2 Million CNY | 90.99% |
| 2010 Q1 | 13.99 Million CNY | -51.77% |
| 2010 FY | - CNY | 52.94% |
| 2009 Q2 | 20.98 Million CNY | 66.55% |
| 2009 Q1 | 12.6 Million CNY | -62.07% |
| 2009 FY | - CNY | 13.9% |
| 2009 Q4 | 29.01 Million CNY | -2.26% |
| 2009 Q3 | 29.68 Million CNY | 41.46% |
| 2008 Q3 | 18.45 Million CNY | 0.0% |
| 2008 FY | - CNY | 59.68% |
| 2008 Q4 | 33.22 Million CNY | 80.03% |
| 2007 FY | - CNY | 188.32% |
| 2006 FY | - CNY | 0.0% |